Abstract: Inflammatory diseases in the CNS can be treated or alleviated by the administration of an oligonucleotide in an amount sufficient to reduce the influx of mononuclear cells to the central nervous system by down-regulating the expression of at least one cell surface marker. For example multiple sclerosis can be treated or at least alleviated, by the administration of an oligonucleotide in a dose effective to inhibit or reduce the influx of mononuclear and/or autoaggressive cells to the central nervous system. The oligonucleotide can be used alone, or in combination with other treatment strategies.

Abstract: Methods for reducing recruitment, migration, or both recruitment and migration of polymorphonuclear cells to a site of inflammation in an organ of a human patient comprise administering locally to the organ or systemically to the patient in need thereof an isolated oligonucleotide selected from the group consisting of SEQ ID NO: 8 (IDX9059); SEQ ID NO: 14 (IDX9052); SEQ ID NO: 7 (IDX9054); SEQ ID NO: 6 (IDX9045); SEQ ID NO: 1 (IDX9005); SEQ ID NO: 9 (IDX9074); SEQ ID NO: 3 (IDX9022); SEQ ID NO: 2 (IDX9010); SEQ ID NO: 4 (IDX9030); and SEQ ID NO: 13 (IDX0150).

Abstract: Methods for reducing recruitment, migration, or both recruitment and migration of polymorphonuclear cells to a site of inflammation in an organ of a human patient comprise administering locally to the organ or systemically to the patient in need thereof an isolated oligonucleotide selected from the group consisting of SEQ ID NO: 8 (IDX9059); SEQ ID NO: 14 (IDX9052); SEQ ID NO: 7 (IDX9054); SEQ ID NO: 6 (IDX9045); SEQ ID NO: 1 (IDX9005); SEQ ID NO: 9 (IDX9074); SEQ ID NO: 3 (IDX9022); SEQ ID NO: 2 (IDX9010); SEQ ID NO: 4 (IDX9030); and SEQ ID NO: 13 (IDX0150).

Abstract: A therapeutically effective amount of an oligonucleotide is capable of influencing the properties and behavior of polymorphonuclear cells, e.g. suppressing endothelial adhesion and transmigration of said cells, and through this mechanism reduce the recruitment and/or migration of polymorphonuclear cells to a site of inflammation.

Abstract: Inflammatory diseases in the CNS can be treated or alleviated by the administration of an oligonucleotide in an amount sufficient to reduce the influx of mononuclear cells to the central nervous system by down-regulating the expression of at least one cell surface marker. For example multiple sclerosis can be treated or at least alleviated, by the administration of an oligonucleotide in a dose effective to inhibit or reduce the influx of mononuclear and/or autoaggressive cells to the central nervous system. The oligonucleotide can be used alone, or in combination with other treatment strategies.

Abstract: Inflammatory diseases in the CNS can be treated or alleviated by the administration of an oligonucleotide in an amount sufficient to reduce the influx of mononuclear cells to the central nervous system by down-regulating the expression of at least one cell surface marker. For example multiple sclerosis can be treated or at least alleviated, by the administration of an oligonucleotide in a dose effective to inhibit or reduce the influx of mononuclear and/or autoaggressive cells to the central nervous system. The oligonucleotide can be used alone, or in combination with other treatment strategies.

Abstract: Isolated and substantially purified oligonucleotide compounds have been shown to be effective in reducing swelling and edema. Novel methods and substances are presented for the prevention, alleviation or treatment of edema of various aetiology.

Abstract: The present invention relates to a process for producing potassium formate. Formaldehyde, potassium hydroxide and isobutyraldehyde are reacted in water, at a molar ratio of 1.0:1.0:1.0 to 3.0:2.0:1.0 and at a temperature of 0-1000 C, preferably 30-700 C. The obtained reaction solution is neutralised to pH 4-6 and evaporated in a first step, whereby two phases are obtained, one organic phase and one aqueous phase, the latter comprising the main part of the potassium formate. The organic phase is subsequently separated from the aqueous phase, where after a final evaporation of the aqueous phase takes place at a pressure of 0.0-1.0 bar and a temperature of 160-2500 C, to obtain a melt of potassium formate. Water is added followed by filtration resulting in a solution having a content of >99% by weight of potassium formate, calculated on a water free basis.

Abstract: A therapeutically effective amount of an oligonucleotide is capable of influencing the properties and behaviour of polymorphonuclear cells, e.g. suppressing endothelial adhesion and transmigration of said cells, and through this mechanism reduce the recruitment and/or migration of polymorphonuclear cells to a site of inflammation.

Abstract: Inflammatory diseases in the CNS can be treated or alleviated by the administration of an oligonucleotide in an amount sufficient to reduce the influx of mononuclear cells to the central nervous system by down-regulating the expression of at least one cell surface marker. For example multiple sclerosis can be treated or at least alleviated, by the administration of an oligonucleotide in a dose effective to inhibit or reduce the influx of mononuclear and/or autoaggressive cells to the central nervous system. The oligonucleotide can be used alone, or in combination with other treatment strategies.

Abstract: A caseless rotor assembly is provided. The caseless rotor assembly includes a rotor shaft, a high pressure portion with a high pressure rotor blade, a low pressure portion with a low pressure rotor blade, and a common wall between the high pressure portion and the low pressure portion. The common wall extends radially from the rotor shaft. The common wall itself includes a shaft end oriented towards the rotor shaft and an outer end on the other side of the common wall, oriented radially outwards. Additionally, the common wall surrounds circularly the rotor shaft.

Abstract: Isolated and substantially purified oligonucleotide compounds have been shown to be effective in reducing swelling and edema. Novel methods and substances are presented for the prevention, alleviation or treatment of edema of various aetiology.

Abstract: The present invention relates to a process for producing potassium formate. Formaldehyde, potassium hydroxide and isobutyraldehyde are reacted in water, at a molar ratio of 1.0:1.0:1.0 to 3.0:2.0:1.0 and at a temperature of 0-1000 C, preferably 30-700 C. The obtained reaction solution is neutralised to pH 4-6 and evaporated in a first step, whereby two phases are obtained, one organic phase and one aqueous phase, the latter comprising the main part of the potassium formate. The organic phase is subsequently separated from the aqueous phase, where after a final evaporation of the aqueous phase takes place at a pressure of 0.0-1.0 bar and a temperature of 160-2500 C, to obtain a melt of potassium formate. Water is added followed by filtration resulting in a solution having a content of >99% by weight of potassium formate, calculated on a water free basis.

Abstract: This invention relates to compounds, compositions, and methods useful for modulating the expression and activity of NF-kappa-B by RNA interference (RNAi) using small nucleic acid molecules, such as short interfering nucleic acid (siNA), short interfering RNA (siRNA) and double-stranded RNA (dsRNA). Furthermore the invention provides methods for preventing, treating or alleviating NF-kappa-B dependent diseases whereby NF-kappa-B is believed to play a role in the pathogenesis of a disease in a subject, preferably a human, by administration of a therapeutic effective and in a pharmacologically accepted form, the siRNA compounds of the invention.

Abstract: Process for the production of di-trimethylolpropane (di-TMP), which comprises subjecting a solution containing less than 3 per cent by weight, preferably less than 1 per cent by weight of water, free trimethylolpropane (TMP) and/or partial ester between TMP and a monocarboxylic acid or its anhydride having 1-4 carbon atoms in the chain, which partial ester on average contains 1.0-2.5, preferably 1.0-2.0 ester groups per molecule to an etherification reaction by heating to 50.degree.-200.degree. C., preferably 70.degree.-190.degree. C. in the presence of an acid catalyst in solid state or in dissolved state until at most 30%, preferably at most 15% of the total content of free TMP and partial ester of TMP in the solution has been etherified to free di-TMP and partial ester of di-TMP respectively, at the same time continuously removing etherification water formed at the etherification reaction under vacuum at a pressure of 0.1-200 mm Hg, preferably 0.